A European survey of patients with idiopathic pulmonary fibrosis (IPF) found that patients well understand the disease’s significant physical and emotional impact on their quality of life, and are frustrated by a perceived lack of quality IPF information and public understanding. The study also underscored the beneficial role of patients’ caregivers and specialist nurses, where available.
A new article that reviews available treatment options for idiopathic pulmonary fibrosis (IPF) took a critical but positive look at available research information for OFEV (nintedanib). The article focuses on the clinical evidence supporting nintedanib as an IPF treatment and on the drug’s pharmacological characteristics. The article, titled “Idiopathic…
Idiopathic pulmonary fibrosis patients experiencing acute exacerbations (IPF-AE) who have a history of immunosuppression and high-dose steroid use are likely to have measurably worse survival outcomes than IPF-AE patients not under such treatment, a new study reported. The research article, “Survival in Idiopathic pulmonary fibrosis acute exacerbations: the non-steroid approach,” was published…
James Doohan was a Canadian actor best known for his role as Montgomery “Scotty” Scott in the television and film series Star Trek. Doohan died on July 20, 2005, at his home in Redmond, Washington due to complications of pulmonary fibrosis, which was believed to be from…
In this map, you can see the location of PF Warrior Patients, caregivers and support Groups along with care center network locations. Learn more about pulmonary fibrosis: https://bit.ly/1lfMsiZ…
Researchers from a large number of international institutions have published an integrated analysis showing that long-term treatment with pirfenidone (Esbriet, Genentech, Roche) in patients with idiopathic pulmonary fibrosis (IPF) can be considered safe. The study, “Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of…
Read the articles here: 1. Tissue Engineering Grows New Lungs in Lab That Could Revolutionize IPF Treatment 2. NY Times Covers Story of IPF Patient’s Progress with Esbriet Treatment 3. IPF Disease Carries High Economic and Healthcare Burden…
Gilead Sciences, Inc. recently announced in a press release that it is stopping its RAINIER Phase II clinical trial testing the investigational monoclonal antibody simtuzumab in patients with idiopathic pulmonary fibrosis (IPF), noting that the experimental therapy did not demonstrate efficacy in treating the disease. Simtuzumab is a humanized monoclonal…
It’s that time of year again. I take you through why I dislike New Year’s resolutions and a simple DIY to help you make the most of your 2016, especially if you’re a transplant recipient or have a chronic illness. If you would like to see more videos like…
https://www.youtube.com/watch?v=a9D2HUyud-k Learn more about Pulmonary Fibrosis: https://bit.ly/1lfMsiZ Pulmonary Fibrosis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of…
Get regular updates to your inbox.
